ArticleACS chemical neuroscience2017
Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[
Open access · greenAbstract read
In one paragraph
Article in ACS chemical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Discovery of N-[2-(4-methylquinolin-2-yl)phenyl]acetamidine as a new potent nitric oxide synthase inhibitor against glioma progression.Molecular diversity · 2026Article
- Synthesis, Biological Evaluation, and Computational Study of Pyridine- and Indazole-Based Inhibitors of the Inducible Nitric Oxide Synthase as Promising Antipsoriatic Agents.ACS pharmacology & translational science · 2026Article
- Formal Synthesis ofMolecules (Basel, Switzerland) · 2026Article
- Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2.ACS pharmacology & translational science · 2024Article
- A novel monoacylglycerol lipase-targetedActa pharmacologica Sinica · 2022Article
- Synthesis and Characterization of 5-(2-Fluoro-4-[Journal of medicinal chemistry · 2022Article
- Synthesis and Characterization of [Molecular imaging and biology · 2021Article
- Design, Synthesis, and Characterization of Benzimidazole Derivatives as Positron Emission Tomography Imaging Ligands for Metabotropic Glutamate Receptor 2.Journal of medicinal chemistry · 2020Article
- Identification and Development of a New Positron Emission Tomography Ligand 4-(2-Fluoro-4-[Journal of medicinal chemistry · 2020Article
- A Review of Molecular Imaging of Glutamate Receptors.Molecules (Basel, Switzerland) · 2020Review
- Synthesis and preliminary studies ofTheranostics · 2020Article
- Design, Synthesis, and Evaluation of Reversible and Irreversible Monoacylglycerol Lipase Positron Emission Tomography (PET) Tracers Using a "Tail Switching" Strategy on a Piperazinyl Azetidine Skeleton.Journal of medicinal chemistry · 2019Article
- In Vitro and in Vivo Evaluation ofJournal of medicinal chemistry · 2018Article
- Design and Synthesis of mGluACS medicinal chemistry letters · 2017Article
- Design and Synthesis ofACS medicinal chemistry letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Xiaofei ZhangNuclear Medicine and Molecular Imaging, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Katsushi KumataDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.
Tomoteru YamasakiDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.
Ran ChengNuclear Medicine and Molecular Imaging, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Akiko HatoriDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.
Longle MaNuclear Medicine and Molecular Imaging, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Yiding ZhangDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.
Lin XieDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.
Lu WangNuclear Medicine and Molecular Imaging, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.
Hye Jin KangDepartment of Pharmacology & National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27515, United States.
Douglas J ShefflerCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute , La Jolla, California 92037, United States.
Nicholas D P CosfordCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute , La Jolla, California 92037, United States.
Ming-Rong ZhangDepartment of Radiopharmaceutics Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology , Chiba 263-8555, Japan.ORCID 0000-0002-3001-9605
Steven H LiangNuclear Medicine and Molecular Imaging, Massachusetts General Hospital , Boston, Massachusetts 02114, United States.ORCID 0000-0003-1413-6315
National Institutes for Quantum Science and Technology · JPHarvard University · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of North Carolina at Chapel Hill · US
Funding
Lead optimization of Novel mGlu2 Negative Allosteric ModulatorsR01MH106865 · NIMH · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COSFORD, NICHOLAS DAVID, DER-AVAKIAN, ANDRE · 2016 to 2018
$2.5MNew PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927kNIDA NIH HHS K01 DA038000NIMH NIH HHS R01 MH106865
Abstract
Metabotropic glutamate 2 receptors (mGlu
Indexed as
Positron-Emission TomographyPyrrolidinesQuinolinesRadiopharmaceuticalsAdhesins, Escherichia coliAllosteric RegulationAnimalsATP Binding Cassette Transporter, Subfamily G, Member 2AutoradiographyBrainDrug DesignHumansMagnetic Resonance ImagingMaleMice, KnockoutMice, Mutant Strains7-((2,5-dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-(11C)methoxyphenyl) quinoline-2-carboxamideAbcg2 protein, mouseAdhesins, Escherichia coliATP Binding Cassette Transporter, Subfamily G, Member 2HEK protein, E colimetabotropic glutamate receptor 2metabotropic glutamate receptor 3PyrrolidinesQuinolinesRadiopharmaceuticalsReceptors, Metabotropic Glutamate11Cmetabotropic glutamate receptor 2mGlu2negative allosteric modulatorPositron emission tomography
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.